### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

---

**1. Name and Address of Reporting Person**

LIDDY EDWARD M

1 N. WAUKEGAN ROAD

**2. Issuer Name and Ticker or Trading Symbol**

AbbVie Inc. [ ABBV ]

**3. Date of Earliest Transaction (Month/Day/Year)**

03/31/2022

**4. If Amendment, Date of Original Filed (Month/Day/Year)**

**5. Relationship of Reporting Person(s) to Issuer**

Director 10% Owner

Officer (give title below) Other (specify below)

**6. Individual or Joint/Group Filing (Check Applicable Line)**

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

---

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Code</th>
<th>4. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>5. Securities Acquired (A) or Disposed Of (D) (Instr. 3)</th>
<th>6. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>7. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>8. Ownership Code: Beneficial (B) or Record (R) (Instr. 4)</th>
<th>9. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Common Stock</td>
<td>03/03/2022</td>
<td>A</td>
<td></td>
<td>(A) or (D)</td>
<td>(A) or (D)</td>
<td>Direct (D)</td>
<td>Beneficial (B)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$162.11</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Explanations:**

1. **Director fees credited to stock equivalent units accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.**

2. **Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.**

---

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Code</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Equivalent Units</td>
<td>03/31/2022</td>
<td>A</td>
<td>177</td>
<td>(A) or (D)</td>
<td>(i)</td>
<td>Common Stock</td>
<td>$162.11</td>
<td>28,474(1)</td>
<td>Direct (D)</td>
<td></td>
</tr>
</tbody>
</table>

**Explanation:**

**1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.**

**2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.**

---

**Reminder:** Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


**Note:** File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 8 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

---

**Steven L. Scrogam, attorney**

梼梼 in-fact for Edward M. Liddy

04/04/2022

**Signature of Reporting Person**

Date